This large national cohort study followed-up pregnant women admitted to hospital and found to have laboratory-confirmed influenza A(H1N1) 2009 infection during the autumn-winter wave of the 2009 pandemic. The main objective was determining any adverse pregnancy outcomes attributable to the infection.
Due to an association that was observed in the United States between a swine-flu based human influenza vaccine developed in 1976 and the disease acute polyneuropathy Guillain-Barré syndrome (GBS) (1,2), GBS was one of the adverse events that was monitored in Europe and North America (3) following the 2009 influenza pandemic vaccination campaigns.
This article, included in The Journal of Infectious Diseases special supplement on measles and rubella, provides an overview of the affected groups and the public settings in which measles transmission occurred in Europe in 2005–2009.
The authors present an appraisal of the pneumococcal epidemiological situation in 11 Central European countries. Data are based on study findings presented at the 12th Central European Vaccine Advisory Group (CEVAG) meeting, held on 21–22 May 2010 in Sofia, Bulgaria, and a literature review of the PubMed database.
ECDC has previously summarised information concerning the appearance of narcolepsy following the use of a specific pandemic vaccine (Pandemrix®) in children and adolescents in three European Countries.
The objective of WHO’s Global Influenza Vaccine Action Plan (which began in 2006) is to increase the use and supply of influenza vaccines on a routine basis.
56 adult patients with PCR confirmed P. knowlesi malaria from Sabah are described. 22 (39%) of these had strictly defined severe malaria including respiratory distress, acute renal failure and shock.
This review outlines how increasing modalities of travel, such as aeromedical evacuation of civilians and of military personnel, medical tourism and any shared healthcare across countries, are risks for the transmission of multidrug-resistant organisms via the patient, from country to country.
In recent years a controversial topic has been whether or not antivirals, specifically the neuraminidase inhibitors, oseltamivir and zanamivir, reduce the likelihood of severe complications of seasonal or pandemic influenza if given soon after infection with influenza viruses.